EyePoint Pharmaceuticals reported a significant increase in total net revenue for Q1 2025, primarily driven by deferred revenue recognition from the out-license of YUTIQ US rights. The company continues to make strong progress in its Phase 3 wet AMD clinical trials for DURAVYU, with enrollment exceeding expectations, reinforcing confidence in enrollment completion in 2H 2025 and a first-to-market advantage. Despite increased operating expenses due to clinical trial costs, the company maintains a strong cash position, providing a runway into 2027.

EyePoint Pharmaceuticals' Q4 2024 revenue declined to $11.6 million, down from $14.0 million in Q4 2023, due to lower license and royalty revenue. Net loss widened to $41.4 million, driven by increased R&D expenses related to DURAVYU’s ongoing Phase 3 clinical trials. The company maintains a strong cash position of $371 million, providing runway into 2027.

EyePoint Pharmaceuticals reported a total net revenue of $10.5 million for the third quarter ended September 30, 2024, compared to $15.2 million for the quarter ended September 30, 2023. The net loss was $29.4 million, or ($0.54) per share, compared to a net loss of $12.6 million, or ($0.33) per share, for the prior year period. Cash and investments totaled $253.8 million at September 30, 2024.

EyePoint Pharmaceuticals reported total net revenue of $9.5 million for the second quarter ended June 30, 2024, compared to $9.1 million for the same period in 2023. The company's cash and investments totaled $280.2 million as of June 30, 2024.

EyePoint Pharmaceuticals reported total net revenue of $11.7 million for the first quarter ended March 31, 2024, compared to $7.7 million for the same period in 2023. The company's operating expenses totaled $45.0 million, and net loss was $29.3 million, or ($0.55) per share. Cash and investments totaled $299.3 million as of March 31, 2024.

EyePoint Pharmaceuticals reported total net revenue of $14.0 million for the quarter ended December 31, 2023, compared to $10.5 million for the same period in 2022. The company's cash and investments reached $331 million, expected to fund operations through topline data for Phase 3 trials of EYP-1901 for wet AMD in 2026.

EyePoint Pharmaceuticals reported total net revenue of $15.2 million for the third quarter ended September 30, 2023, compared to $10.0 million for the same period in 2022. The net loss was $12.6 million, or ($0.33) per share, compared to a net loss of $18.4 million, or ($.49) per share, for the prior year period.

EyePoint Pharmaceuticals reported a decrease in total net revenue to $9.1 million compared to $11.6 million for the same quarter last year. The company sold the YUTIQ® franchise for $82.5 million cash plus future royalties, retired all outstanding bank debt, and extended their cash runway into 2025. They are focused on the clinical development of EYP-1901.

EyePoint Pharmaceuticals reported a total net revenue of $7.7 million for the first quarter ended March 31, 2023. YUTIQ net product revenue increased by 60% to $7.4 million compared to the first quarter of 2022. The company's cash and investments totaled $122.5 million as of March 31, 2023.

EyePoint Pharmaceuticals reported total net revenue of $10.5 million for the quarter ended December 31, 2022, compared to $11.5 million for the quarter ended December 31, 2021. Net loss was $43.5 million, or ($1.16) per share, compared to a net loss of $19.4 million, or ($.59) per share, for the prior year period.

EyePoint Pharmaceuticals reported a strong quarter with the initiation of two Phase 2 clinical trials for EYP-1901 in wet AMD and NPDR, along with net product revenue of $9.7 million, a 13% increase from Q3 2021.

EyePoint Pharmaceuticals reported a net product revenue of $11.3 million in Q2 2022, a 30% increase from Q2 2021. The company's total net revenue was $11.6 million compared to $9.0 million for the quarter ended June 30, 2021.

EyePoint Pharmaceuticals reported a strong first quarter with $9.0 million in net product revenue, a 32% increase from the first quarter of last year. The company is well-capitalized to continue advancing its pipeline, including two expected Phase 2 clinical trial initiations of EYP-1901 in wet AMD in Q3 and in NPDR later in the second half of 2022.

EyePoint Pharmaceuticals reported Q4 2021 financial results, featuring a rise in total net revenue to $11.5 million compared to $7.1 million in Q4 2020. Net product revenue increased to $11.2 million from $6.7 million year-over-year, driven by record customer demand for YUTIQ and DEXYCU. However, operating expenses also increased, leading to a net loss of $19.4 million, or ($0.59) per share, compared to a net loss of $15.5 million, or ($1.07) per share, in the prior year period. The company's cash and investments totaled $211.6 million as of December 31, 2021.

EyePoint Pharmaceuticals reported Q3 2021 financial results, with net product revenues increasing by 49% compared to Q3 2020. The company is advancing its pipeline, with positive safety data from the Phase 1 DAVIO trial of EYP-1901 for wet AMD.

EyePoint Pharmaceuticals reported a strong second quarter, marked by significant progress in the Phase 1 DAVIO trial for EYP-1901 and a substantial increase in net product revenue, driven by growing customer demand for DEXYCU and YUTIQ.

EyePoint Pharmaceuticals reported a productive first quarter with a solid commercial performance and advancements in their pipeline, including the initiation of the Phase 1 DAVIO clinical trial for EYP-1901 and the completion of a $115.1 million follow-on financing.

EyePoint Pharmaceuticals reported a net revenue of $7.1 million for Q4 2020, a decrease from $8.6 million in Q4 2019. The company experienced a net loss of $15.5 million, or $1.07 per share, compared to a net loss of $10.4 million, or $0.98 per share, in the prior year quarter. Despite the revenue decrease, EyePoint highlighted progress with EYP-1901 and improvements to the balance sheet, including a $115.1 million follow-on financing completed in February 2021.

EyePoint Pharmaceuticals reported total net revenue of $15.7 million for the third quarter of 2020, compared to $2.5 million for the same period in 2019. Net product revenue was $5.8 million, with $3.5 million from YUTIQ and $2.3 million from DEXYCU. The company's net loss was $3.8 million, or $0.03 per share, compared to a net loss of $15.6 million, or $0.15 per share, for the prior year quarter. Cash and cash equivalents as of October 31, 2020, were $30.5 million.

EyePoint Pharmaceuticals reported Q2 2020 financial results, with total revenues of $4.1 million and net product revenues of $3.7 million, impacted by the COVID-19 pandemic. A U.S. commercial alliance with ImprimisRx was established to expand the reach of DEXYCU. Jay S. Duker, M.D., joined as Chief Strategic Scientific Officer to lead EYP-1901 development efforts. EYP-1901 remains on track for a Q4 IND filing.

EyePoint Pharmaceuticals reported total net revenue of $7.5 million for the first quarter ended March 31, 2020, compared to $2.0 million for the same period in 2019. Net product revenue was $4.7 million, with $3.6 million from YUTIQ and $1.1 million from DEXYCU. The company's cash and cash equivalents totaled $26.3 million at the end of the quarter.

EyePoint Pharmaceuticals reported total revenues of $8.6 million for Q4 2019, driven by net product revenues of $7.9 million from DEXYCU and YUTIQ. Customer demand for DEXYCU and YUTIQ increased significantly compared to Q3 2019. The company is advancing EYP-1901 towards clinical development and expects continued customer demand growth in 2020.